Vaccinex (VCNX) Revenue & Revenue Breakdown
Vaccinex Revenue Highlights
Latest Revenue (Y)
$570.00K
Latest Revenue (Q)
$52.00K
Main Segment (Y)
Exclusive Product License
Main Geography (Y)
Exclusive Product License
Vaccinex Revenue by Period
Vaccinex Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $570.00K | 470.00% |
| 2022-12-31 | $100.00K | -88.89% |
| 2021-12-31 | $900.00K | 1700.00% |
| 2020-12-31 | $50.00K | -90.44% |
| 2019-12-31 | $523.00K | -27.76% |
| 2018-12-31 | $724.00K | 704.44% |
| 2017-12-31 | $90.00K | -71.52% |
| 2016-12-31 | $316.00K | - |
Vaccinex generated $570.00K in revenue during NA 2023, up 470.00% compared to the previous quarter, and up 78.73% compared to the same period a year ago.
Vaccinex Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $52.00K | -77.59% |
| 2024-06-30 | $232.00K | 123.08% |
| 2024-03-31 | $104.00K | -126.94% |
| 2023-12-31 | $-386.00K | -2030.00% |
| 2023-09-30 | $20.00K | 100.00% |
| 2023-06-30 | - | -100.00% |
| 2023-03-31 | $550.00K | 1000.00% |
| 2022-12-31 | $50.00K | - |
| 2022-09-30 | $50.00K | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | -100.00% |
| 2021-12-31 | $850.00K | 1600.00% |
| 2021-09-30 | $50.00K | 100.00% |
| 2021-06-30 | - | -100.00% |
| 2021-03-31 | $850.00K | 1600.00% |
| 2020-12-31 | $50.00K | - |
| 2020-09-30 | $50.00K | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | -100.00% |
| 2019-09-30 | $404.00K | 1516.00% |
| 2019-06-30 | $25.00K | -73.40% |
| 2019-03-31 | $94.00K | -51.55% |
| 2018-12-31 | $194.00K | -2.02% |
| 2018-09-30 | $198.00K | 57.14% |
| 2018-06-30 | $126.00K | -38.83% |
| 2018-03-31 | $206.00K | 128.89% |
| 2017-12-31 | $90.00K | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | - |
Vaccinex generated $52.00K in revenue during Q3 2024, up -77.59% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Vaccinex Revenue Breakdown
Vaccinex Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 21 | Dec 19 |
|---|---|---|---|
| Exclusive Product License | $500.00K | $850.00K | - |
| Exclusive Research Tool License | - | - | $100.00K |
| Exclusive Product License Option | - | - | $300.00K |
Vaccinex's latest annual revenue breakdown by segment (product or service), as of Dec 23: Exclusive Product License (100.00%).
Quarterly Revenue by Product
| Product/Service | Sep 22 | Sep 21 | Mar 21 | Sep 19 |
|---|---|---|---|---|
| Exclusive Product License | $50.00K | $50.00K | $850.00K | $100.00K |
| License | - | - | $850.00K | - |
| Exercise Of Product Option | - | - | - | $300.00K |
Vaccinex's latest quarterly revenue breakdown by segment (product or service), as of Sep 22: Exclusive Product License (100.00%).
Vaccinex Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 21 | Dec 19 |
|---|---|---|
| Exclusive Product License | $850.00K | - |
| Exclusive Product License Option | - | $300.00K |
| Exclusive Research Tool License | - | $100.00K |
Vaccinex's latest annual revenue breakdown by geography, as of Dec 21: Exclusive Product License (100.00%).
Quarterly Revenue by Country
| Country | Sep 22 | Sep 21 | Mar 21 | Sep 19 |
|---|---|---|---|---|
| Exclusive Product License | $50.00K | $50.00K | $850.00K | $100.00K |
| License | - | - | $850.00K | - |
| Exercise Of Product Option | - | - | - | $300.00K |
Vaccinex's latest quarterly revenue breakdown by geography, as of Sep 22: Exclusive Product License (100.00%).
Vaccinex Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| SABS | SAB Biotherapeutics | $2.24M | $263.14K |
| VCNX | Vaccinex | $570.00K | $52.00K |
| ANEB | Anebulo Pharmaceuticals | - | - |
| FBRX | Forte Biosciences | - | - |
| TARA | Protara Therapeutics | - | - |
| ERAS | Erasca | - | - |
| FWBI | Entero Therapeutics | - | - |
| RNXT | RenovoRx | - | - |
| GOVX | GeoVax Labs | - | $300.68K |
| MNPR | Monopar Therapeutics | - | - |
| SRZN | Surrozen | - | - |
| ELDN | Eledon Pharmaceuticals | - | - |
| SLRX | Salarius Pharmaceuticals | - | - |